GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (FRA:RGO) » Definitions » Valuation Rank

Regeneron Pharmaceuticals (FRA:RGO) Valuation Rank


View and export this data going back to 1990. Start your Free Trial

What is Regeneron Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Regeneron Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals (FRA:RGO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (FRA:RGO) » Definitions » Valuation Rank
Comparable Companies
VRTX MRNA BNTX ALNY BGNE BMRN RPRX SRPT INCY UTHR OCSE:NOVO B ASX:CSL XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX OCSE:GMAB SHSE:603392 SZSE:300122 XKRX:028300
Traded in Other Exchanges
REGN:USA REGN:Mexico RGO:Germany REGN34:Brazil
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Website
https://www.regeneron.com
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).